Novartis’ cover photo
Novartis

Novartis

Pharmaceutical Manufacturing

Basel, Baselstadt 4,557,387 followers

About us

Novartis is an innovative medicines company. Every day, working to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide. Find out more at https://www.novartis.com See our community guidelines: https://go.novartis.social/3Nboxki

Website
http://www.novartis.com

External link for Novartis

Industry
Pharmaceutical Manufacturing
Company size
10,001+ employees
Headquarters
Basel, Baselstadt
Type
Public Company
Specialties
Cardiovascular, Immunology, Neuroscience, Solid Tumors, Hematology, Chemistry, xRNA, Radioligand, and Gene and cell therapy

Locations

Employees at Novartis

See all employees

Updates

  • View organization page for Novartis

    4,557,387 followers

    Congratulations toKorab Zuka for ranking #10 in Sustainability Magazine's Top 250 Sustainability Leaders for 2026.As Global Head of Social Impact and Chief Sustainability Officer, Korab leads the integration of social impact and sustainability across Novartis, ensuring they serve as strategic levers for long term value creation.Behind recognition like this is the dedication of the many teams across Novartis and the partners we work with who are committed to improving health outcomes while achieving our goal of net zero by 2040.

    • No alternative text description for this image
  • View organization page for Novartis

    4,557,387 followers

    Our Commitment to Patients and Caregivers is more than a promise – it delivers meaningful, measurable impact.In 2025, eight years after we pledged to embed patient perspectives into our decision making, we continued to strengthen access to medicines, enhance transparency in clinical research, and deepen collaboration with patient communities around the world.By keeping patients at the heart of our work, we focus on what matters most: bringing forward innovative medicines that create real value for people and for health systems.Our full 2025 results have now been published. Follow the link to explore how we are reimagining medicine together:https://lnkd.in/g_WibjHX#PatientCentricity#ReimaginingMedicine

    Novartis Commitment to Patients and Caregivers – 2025 Impact
  • View organization page for Novartis

    4,557,387 followers

    At Novartis, we take on the toughest challenges in healthcare, with a goal to deliver breakthrough innovations that can redefine the future of medicine. Today, we are proud to share that two Novartis leaders have been recognized as part ofTIME 100 Most Influential People in Health. This acknowledgment reinforces our unwavering commitment to innovation in healthcare, from bringing cutting-edge cancer care to patients with radioligand therapies, to taking on the biggest issues in global health by driving the next generation of antimalarials. Congratulations toVictor Bultó andThierry Diagana and to all our teams who have contributed to this pioneering work. Access our web special to learn more:https://lnkd.in/g_xNPquF#ReimaginingMedicine |#TIME

  • View organization page for Novartis

    4,557,387 followers

    We’re naming what’s in for 2026 – the habits that help us breathe, focus, and feel human at work. And we’re letting go of what’s out – the pressure, the autopilot, the quiet “I’m fine” that hides a lot.Because life is… a lot. And everyone deserves a workplace that sees that, supports that, and makes space for it. Here’s what we’re choosing more of this year – and what we’re leaving behind together. What about you? What’s in and out for you in 2026?

  • View organization page for Novartis

    4,557,387 followers

    For decades, society has known that a healthy diet can aid in the prevention of many cardiovascular diseases. And yet, these illnesses remain leading killers around the world. This is particularly true in the United States and even more so in cities like Baltimore due to structural challenges. But the Engage with Heart program aims to reverse these inequities by taking on access, affordability, education, and the extra motivation provided by making change together as a community.Read more on Live Magazine.https://lnkd.in/gKWhGjrh#NovartisLive

    Baking a Food Revolution
  • View organization page for Novartis

    4,557,387 followers

    Turning scientific progress into real outcomes requires going further than discovery alone.In Baltimore, a retiree with high blood pressure received his first screening since retirement through Engage with Heart, an initiative we support to bring heart health resources into trusted community settings like churches and senior groups. This reflects a broader focus: pairing innovation in medicine with innovation in how health systems reach underserved populations.In 2025, we reached 300 million patients across 118 countries. We invested USD 10.3 billion in core R&D, received 29 approvals in priority markets, and launched the first malaria treatment for newborns and young infants from 2 to under 5kg. We also continued progress on climate commitments because protecting planetary health supports human health.Behind these milestones are the partners, colleagues, and communities who make this work possible.Swipe to learn more about our 2025 impact.

  • View organization page for Novartis

    4,557,387 followers

    Novartis is breaking ground on a new Biomedical Research center in San Diego, California. The facility will enable end to end drug discovery across key disease areas and expand technology platform capabilities to advance the company’s pipeline for patients. Read our press release to learn more:https://lnkd.in/gfHskm_G#NovartisNews#ReimaginingMedicine

    Novartis breaks ground on San Diego Biomedical Research center
  • View organization page for Novartis

    4,557,387 followers

    Novartis delivered high single-digit sales growth in 2025 and continued to advance our pipeline. We advanced several potential multi-blockbusters and strengthened our pipeline through strategic deals. In 2026, we expect to grow through the largest patent expiry in Novartis history, underscoring the strength of our business, and remain well on track to deliver our mid-term guidance.Link to press release:https://lnkd.in/gTpESPk6#NVSQ425

  • View organization page for Novartis

    4,557,387 followers

    On February 4th,#WorldCancerDay, we stand with people affected by cancer around the world – amplifying their voices and advocating for better care.Cancer touches us all, one way or another – and there is still much more to do. TheUnion for International Cancer Control (UICC)'s#UnitedByUnique global campaign puts people at the center of care and their stories at the heart of the conversation. It recognizes that every cancer experience is unique – and that by sharing these stories we can raise awareness, inspire change and help drive better outcomes for everyone affected by cancer.Learn more:https://lnkd.in/gmBH8sHa

    • No alternative text description for this image
  • View organization page for Novartis

    4,557,387 followers

    At the World Economic Forum Annual Meeting, theNovartis Foundation highlighted the unique role that cities can play in shifting health systems from reactive care to proactive, predictive approaches that reduce cardiometabolic risk and deliver measurable societal and economic returns. With hypertension, diabetes, and heart disease rising worldwide, moving towards proactive, data‑driven disease prevention is no longer optional; it’s critical. Alongside partners, the Foundation focused on how technology, AI and cross‑sector collaboration through programs such as CARDIO4Cities can turn that urgency into measurable impact. ➡️ Swipe to learn more about The Novartis Foundation at#WEF26.

Join now to see what you are missing

  • Find people you know at Novartis
  • Browse recommended jobs for you
  • View all updates, news, and articles
Join now

Affiliated pages

Similar pages

Browse jobs

Funding

Novartis 2 total rounds

Last Round

Post IPO debt
External Crunchbase Link for last round of funding

US$ 2.5B

See more info oncrunchbase